Since heat shock protein 90 (Hsp90) is highly overexpressed in cancer, it is considered both a tumor marker and a therapeutic target for intervention.

Microtubules need to maintain a dynamic balance between polymerization and depolymerization to accomplish their role in cell division and other functions. Classical tubulin-targeting agents are divided into microtubule stabilizers and tubulin polymerization inhibitors.

Hypoxia, a hallmark of the tumor microenvironment (TME), promotes malignant progression and resistance to chemotherapy and radiotherapy and hence, should be delimitated before treatment initiation. 

The first development candidate has been nominated under a collaboration between Carisma Therapeutics Inc. and Moderna Inc. to discover, develop and commercialize in vivo engineered chimeric antigen receptor monocytes and macrophages (CAR-M) therapeutics for the treatment of cancer.

Breast cancer is a common cause of brain metastases and new research has shown that metastatic cells can invade the meninges not by entering the circulation and crossing the blood-brain barrier, but by traveling along the outer surface of the blood vessels that connect the vertebral bone marrow and the skull.

Signal transducer and activator of transcription 3 (STAT3) plays a key role in cell proliferation observed in colorectal cancer (CRC), where up-regulation of STAT3 accelerates tumorigenesis and promotes metastasis.

Oncopeptides AB has selected its first candidate drug based on the company’s unique platform for small polypeptide-based innate killer engagers (SPiKE). The SPiKE platform uses multispecific constructs, able to bind to multiple targets simultaneously.